home / stock / abvc / abvc news


ABVC News and Press, ABVC BioPharma Inc. From 01/06/23

Stock Information

Company Name: ABVC BioPharma Inc.
Stock Symbol: ABVC
Market: NASDAQ
Website: abvcpharma.com

Menu

ABVC ABVC Quote ABVC Short ABVC News ABVC Articles ABVC Message Board
Get ABVC Alerts

News, Short Squeeze, Breakout and More Instantly...

ABVC - How to Find Cheap Penny Stocks to Make Money Trading 

3 Tips for Finding Cheap Penny Stocks Right Now Penny stocks can be a tempting investment opportunity for traders due to their low price point and the potential for large returns. While penny stocks come with a higher level of risk compared to larger, more established stocks, they also of...

ABVC - 5 Hot Penny Stocks Exploding After News This Week

Red Hot Penny Stocks Moving Higher After Headlines One of the go-to strategies for finding penny stocks to buy – at least for some traders – is identifying obvious catalysts. One of the most “obvious” typically comes in the form of company news. It takes more dilig...

ABVC - FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology today announced that the US Food & Drug Administration n...

ABVC - ABVC BioPharma GAAP EPS of -$0.11 beats by $0.09, revenue of $0.04M beats by $0.01M

ABVC BioPharma press release ( NASDAQ: ABVC ): Q3 GAAP EPS of -$0.11 beats by $0.09 . Revenue of $0.04M (-55.6% Y/Y) beats by $0.01M . For further details see: ABVC BioPharma GAAP EPS of -$0.11 beats by $0.09, revenue of $0.04M beats by $0.01M

ABVC - ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

FREMONT, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results f...

ABVC - ABVC Biopharma stock rises on upcoming US patent for ABV-1504 to treat depression

ABVC Biopharma ( NASDAQ: ABVC ) stock rose ~6% on Monday after the company said it received a notice of allowance from the U.S. Patent and Trademark Office for ABV-1504. The patent titled, 'Polygala Extract for the Treatment of Major Depressive Disorder,' outlines ...

ABVC - ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

Fremont, CA - ( NewMediaWire ) - November 07, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that on October 20, 2022, it received a Notice of Allowance fo...

ABVC - Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients

Fremont, CA - ( NewMediaWire ) - November 02, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Cedars-Sinai Medical Center (CSMC, West Hollywood CA)...

ABVC - Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

ABVC BioPharma ( NASDAQ: ABVC ) on Wednesday said it had got an approval from an Australian ethics committee for the phase 2 study plan for its vitreous substitute Vitargus. The company subsequently submitted a clinical trial application to the Australian drug regulator, the T...

ABVC - ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

ABVC Biopharma ( NASDAQ: ABVC ) said on Friday that a Phase II Part 2  study testing its ADHD drug, ABV-1505, currently being conducted at five medical centers in Taiwan, had enrolled 30 subjects and eighteen of the enrolled participants had completed t...

Previous 10 Next 10